RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive is a phase 2/3 interventional study registered as NCT07413939, led by Hoffmann-La Roche, and recruiting when checked on 2026-09-11. Official title: A Two-part, Seamless, Multicenter, Randomised, Open-label, Adaptive Phase II/III Study of the Blood-brain Barrier Penetrant RO7771950 Versus Tucatinib, Both in Combination With Trastuzumab and Capecitabine, in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer, With or Without Central Nervous System Metastases. Planned enrolment is 650 participants (estimated). The study started in 2026-05-21 and primary completion is expected in 2029-05-01. No results have been posted on ClinicalTrials.gov.